Header cover image

South Korean (KOSPI) Biotech Industry Analysis

UpdatedJan 19, 2022
DataAggregated Company Financials
Companies93
  • 7D-12.3%
  • 3M-19.5%
  • 1Y-36.8%
  • YTD-15.5%

Over the last 7 days, the Biotech industry has dropped 12%, driven by a pullback from Celltrion of 15%. Meanwhile, ABL Bio actually outperformed within the industry, gaining 23% in the last week. However, the industry is down 37% over the past year.

Industry Valuation and Performance

Has the South Korean Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Wed, 19 Jan 2022₩78.9t₩9.4t₩787.4b33.6x
Fri, 17 Dec 2021₩97.8t₩9.4t₩780.1b40.7x
Sun, 14 Nov 2021₩94.1t₩9.2t₩986.1b32.9x
Tue, 12 Oct 2021₩96.1t₩9.2t₩986.0b37.5x
Thu, 09 Sep 2021₩117.0t₩9.3t₩946.2b46.3x
Sat, 07 Aug 2021₩114.8t₩9.3t₩909.7b52.6x
Fri, 30 Apr 2021₩101.2t₩9.0t₩979.0b41.7x
Mon, 01 Feb 2021₩96.7t₩8.2t₩501.3b49.6x
Thu, 05 Nov 2020₩80.0t₩7.5t₩291.2b32.5x
Sun, 09 Aug 2020₩87.9t₩6.7t-₩13,176,736,074.0049.2x
Sat, 02 May 2020₩57.2t₩6.1t-₩304,564,934,452.0043.6x
Tue, 04 Feb 2020₩46.7t₩5.8t-₩212,594,028,191.0041.2x
Fri, 08 Nov 2019₩51.3t₩5.5t₩44.0b37.8x
Thu, 01 Aug 2019₩49.7t₩5.4t₩112.2b40.4x
Sun, 05 May 2019₩64.7t₩5.4t₩105.4b42.7x
Wed, 06 Feb 2019₩65.3t₩5.4t₩163.5b40.1x
PE Ratio

40.1x

Total Market Cap: ₩65.3tTotal Earnings: ₩163.5bTotal Revenue: ₩5.4t0%0%0%3 Year10 Year
202020212022

Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 33.6x which is lower than its 3-year average PE of 42.8x. It appears they believe that earnings will not grow as fast as they have historically.

Past Earnings Growth: The earnings for companies in the Biotechs industry have grown 69% per year over the last three years, and revenues for these companies have grown 20% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Biotech industry?

Biotech-12.30%

Industry PE: Investors are most optimistic about the Biotech industry even though it's trading below its 3-year average PE ratio of 42.8x. However analysts are expecting annual earnings growth of 23%, which is lower than the prior year's growth of 67% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years. However this is lower than its past earnings growth rate of 67% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A298380 ABL Bio₩32.10k22.8%
+₩280.4b
18.9%PS150.9x
A142760 Bioleaders₩12.05k42.8%
+₩103.5b
108.5%PS3.5x
A206650 EuBiologics₩33.50k1.2%
+₩14.5b
27.9%PS30.4x
A046210 Panagene₩4.65k6.8%
+₩9.5b
-9.6%n/a
A149300 Apures₩2.38k4.9%
+₩3.1b
-18.9%n/a
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

A068270

₩167.0k

Celltrion

7D

-14.4%

1Y

-45.4%